This article is more than 5 years old. Information may no longer be current.
Cognoptix receives $15 million to develop eye test to identify Alzheimer's
Click Here to Manage Email Alerts
Cognoptix announced that it has closed the first portion of a Series D round of financing for more than $15 million to develop the Sapphire II eye test to identify Alzheimer’s disease by utilizing a beta-amyloid signature.
The Sapphire II detects a specific fluorescent signature of ligand-marked A-beta in the supranucleus region of the human lens, according to the press release.
Sapphire II achieved a sensitivity of 85% and a specificity of 95% in differentiating 20 patients who were clinically diagnosed with probable Alzheimer’s disease from a group of 20 age-matched healthy volunteers in a phase 2 clinical trial, according to Cognoptix.
The Series D investment will fund the trial and the final stages of product development and allow Cognoptix to complete U.S. Food and Drug Administration registration.